EPS for Innoviva, Inc. (INVA) Expected At $0.45

January 5, 2018 - By Marry Poplack

 EPS for Innoviva, Inc. (INVA) Expected At $0.45

Analysts expect Innoviva, Inc. (NASDAQ:INVA) to report $0.45 EPS on February, 8.They anticipate $0.20 EPS change or 80.00 % from last quarter’s $0.25 EPS. INVA’s profit would be $48.60M giving it 7.81 P/E if the $0.45 EPS is correct. After having $0.21 EPS previously, Innoviva, Inc.’s analysts see 114.29 % EPS growth. The stock decreased 0.11% or $0.015 during the last trading session, reaching $14.055. About 144,560 shares traded. Innoviva, Inc. (NASDAQ:INVA) has risen 9.71% since January 5, 2017 and is uptrending. It has underperformed by 6.99% the S&P500.

Innoviva, Inc. engages in the development and commercialization of bio-pharmaceuticals. The company has market cap of $1.52 billion. The Company’s portfolio of respiratory products include RELVAR/BREO ELLIPTA, and ANORO ELLIPTA (umeclidinium bromide/ vilanterol, UMEC/VI). It has a 16.46 P/E ratio. The company, under its the Long-Acting Beta2 Agonist (LABA) collaboration agreement and the strategic alliance agreement with Glaxo Group Limited (GSK), is entitled to receive royalties on the sales of RELVAR/BREO ELLIPTA; and a 15% of any future payments made by GSK under its agreements relating to the combination FF/UMEC/VI and the Bifunctional Muscarinic Antagonist-Beta2 Agonist program, as monotherapy and in combination with other therapeutically active components.

More important recent Innoviva, Inc. (NASDAQ:INVA) news were published by: Streetinsider.com which released: “Form 8-K Innoviva, Inc. For: Dec 19” on December 20, 2017, also Businesswire.com published article titled: “Innoviva and Sarissa Implement Court Order”, Prnewswire.com published: “Pre-Market Technical Scan on Application Software Equities — Innoviva, Intuit …” on January 03, 2018. More interesting news about Innoviva, Inc. (NASDAQ:INVA) was released by: Nasdaq.com and their article: “Validea Joel Greenblatt Strategy Daily Upgrade Report – 1/5/2018” with publication date: January 05, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: